Jose R Corvalan

US Patent:

7037498, May 2, 2006

Filed:

Jan 4, 2002

Appl. No.:

10/038591

Inventors:

Bruce D. Cohen - East Lyme CT, US
Jean Beebe - Salem CT, US
Penelope E. Miller - Mystic CT, US
James D. Moyer - East Lyme CT, US
Jose R. Corvalan - Foster City CA, US
Michael Gallo - North Vancouver, CA

Assignee:

Abgenix, Inc. - Fremont CA
Pfizer Inc - New York NY

International Classification:

A61K 39/395

US Classification:

4241561, 4241331, 4241301, 5303871, 5303873, 53038822, 53038885

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

US Patent:

7109003, Sep 19, 2006

Filed:

Jul 1, 2003

Appl. No.:

10/612497

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Mystic CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Old Lyme CT, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Abgenix, Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C12P 21/08
C12P 21/00
G01N 33/53
C07K 16/28

US Classification:

435 7021, 435 701, 435 702, 435 703, 435 71, 800 6, 53038815, 5303881, 5303882, 53038822, 5303887, 53038875

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

7132281, Nov 7, 2006

Filed:

Feb 10, 2004

Appl. No.:

10/776649

Inventors:

Douglas Charles Hanson - Niantic CT, US
Mark Joseph Neveu - Mystic CT, US
Eileen Elliott Mueller - Old Lyme CT, US
Jeffrey Herbert Hanke - Reading MA, US
Steven Christopher Gilman - Old Lyme CT, US
C. Geoffrey Davis - Burlingame CA, US
Jose Ramon Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C12N 5/10
C12P 21/08

US Classification:

435331, 435325, 435326, 435328, 435 691, 435 696, 435 701, 435 7021

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

US Patent:

7141653, Nov 28, 2006

Filed:

Mar 27, 2003

Appl. No.:

10/401344

Inventors:

Scott Greenfeder - Metuchen NJ, US
Jose Corvalan - Foster City CA, US

Assignee:

Schering Corporation - Kenilworth NJ
Abgenix, Inc. - Fremont CA

International Classification:

C07K 16/24
A61K 39/395

US Classification:

5303871, 5303873, 53038823, 4241301, 4241391, 4241451

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

US Patent:

7288251, Oct 30, 2007

Filed:

Nov 8, 2002

Appl. No.:

10/292088

Inventors:

Vahe Bedian - East Lyme CT, US
Ronald P. Gladue - Stonington CT, US
Jose Corvalan - Foster City CA, US
Xiao-Chi Jia - San Mateo CA, US
Xiao Feng - Union City CA, US

Assignee:

Abgenix, Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 5303871, 5303873, 5303882, 53038822, 5303887, 53038873

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

US Patent:

7338660, Mar 4, 2008

Filed:

Aug 25, 2005

Appl. No.:

11/211917

Inventors:

Vahe Bedian - East Lyme CT, US
Ronald P Gladue - Stonington CT, US
Jose Corvalan - Foster City CA, US
Xiao-Chi Jia - San Mateo CA, US
Xiao Feng - Union City CA, US

Assignee:

Abgenix, Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 5303871, 5303873, 5303882, 53038822, 5303887, 53038873

Abstract:

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

US Patent:

7364736, Apr 29, 2008

Filed:

Jun 25, 2002

Appl. No.:

10/180648

Inventors:

William J. Boyle - Thousand Oaks CA, US
Francis H. Martin - Newbury Park CA, US
Jose R. Corvalan - Foster City CA, US
C. Geoffrey Davis - Burlingame CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA
Amgen Fremont Inc. - Fremont CA

International Classification:

A61K 39/395

US Classification:

4241451, 4241331, 4241351, 4241411, 5303873, 53038824

Abstract:

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

US Patent:

7411057, Aug 12, 2008

Filed:

May 12, 2005

Appl. No.:

11/128900

Inventors:

Douglas C Hanson - Niantic CT, US
Mark J Neveu - Hartford CT, US
Eileen E Mueller - Old Lyme CT, US
Jeffrey H Hanke - Reading MA, US
Steven C Gilman - Cambridge MA, US
C. Geoffrey Davis - Burlingame CA, US
Jose R Corvalan - Foster City CA, US

Assignee:

Amgen Fremont Inc. - Fremont CA
Pfizer Inc. - New York NY

International Classification:

C07H 21/04
C12P 21/08
C12N 1/21
C12N 5/10
C12N 15/11

US Classification:

536 2353, 536 231, 536 235, 435 691, 4352523, 4353201, 435455

Abstract:

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.